These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 26988947)

  • 21. Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia.
    Hegele RA
    J Am Coll Cardiol; 2016 Mar; 67(11):1286-8. PubMed ID: 26988948
    [No Abstract]   [Full Text] [Related]  

  • 22. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
    Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
    Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
    J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
    Lahoz C; Mostaza JM; Pintó X; de la Cruz JJ; Banegas JR; Pedro-Botet J;
    Clin Investig Arterioscler; 2015; 27(1):1-8. PubMed ID: 24882148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
    Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.
    Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J
    Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
    Li L; Zhang M; Su F; Li Y; Shen Y; Shen J; Zhang D
    Lipids Health Dis; 2015 Feb; 14():10. PubMed ID: 25879728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.
    Stein EA; Dann EJ; Wiegman A; Skovby F; Gaudet D; Sokal E; Charng MJ; Mohamed M; Luirink I; Raichlen JS; Sundén M; Carlsson SC; Raal FJ; Kastelein JJP
    J Am Coll Cardiol; 2017 Aug; 70(9):1162-1170. PubMed ID: 28838366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
    Araujo MB; Pacce MS
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Latkovskis G; Saripo V; Gilis D; Nesterovics G; Upena-Roze A; Erglis A
    Atherosclerosis; 2018 Oct; 277():347-354. PubMed ID: 30270070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
    Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
    Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
    Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
    Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
    Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
    Davidson M
    Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.